Related Experiment Videos
N-alkyl-substituted glycopeptide antibiotics
1Antimicrobial Research Centre and Department of Microbiology, University of Leeds, UK.
Expert Opinion on Investigational Drugs
|March 1, 1997
Summary
New N-alkylated glycopeptide antibiotics are being developed to combat vancomycin-resistant enterococci. The lead compound, LY333328, shows promise against resistant Gram-positive cocci infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Medicinal Chemistry
Background:
- Vancomycin is crucial for treating staphylococcal and enterococcal infections, especially resistant strains.
- High-level vancomycin resistance in enterococci poses a significant threat due to potential transfer to other pathogens.
- Development of novel glycopeptides is necessary to overcome emerging antibiotic resistance.
Purpose of the Study:
- To introduce a new class of N-alkylated glycopeptide antibiotics.
- To present LY333328 as a potential therapeutic agent against vancomycin-resistant organisms.
Main Methods:
- Development of novel N-alkylated glycopeptide structures.
- Pre-clinical evaluation of lead compounds (implied).
- Initiation of Phase I clinical trials for LY333328.
Main Results:
- A new series of N-alkylated glycopeptide antibiotics has been synthesized.
- The lead compound, LY333328, demonstrates potential activity against vancomycin-resistant pathogens.
- LY333328 has advanced to Phase I clinical trials.
Conclusions:
- N-alkylated glycopeptides represent a promising new class of antibiotics.
- LY333328 is a potential candidate for treating infections caused by vancomycin-resistant Gram-positive cocci.
- Further clinical evaluation is warranted for LY333328.